Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?

BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal

Drugmakers rush to sign deals on first day of industry conference

Intra-Cellular just downgraded at Morgan Stanley, here's why

J&J to buy Intra-Cellular Therapies for $14.6 billion

J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports

Intra-Cellular's schizophrenia drug meets main goal in late-stage trial